Qiming Venture Partners Portfolio Companies YanYin Technology and ZhuanMa Bio Launch China's First CRISPR Gene Design Tool
The two parties will jointly develop a next-generation CRISPR design application platform, deeply integrating Zuanma Biotech's cutting-edge gene editing technology with YanYin AI's cloud-based R&D platform. This collaboration will deliver unprecedented convenience, precision, and efficiency to CRISPR gene editing users worldwide, dramatically streamlining the design and analysis workflows for gene editing experiments.
China's first CRISPR gene design tool, jointly developed by YanYin Technology and ZhuanMa Bio — both portfolio companies of Qiming Venture Partners — has officially launched, marking a milestone breakthrough for China in core gene editing technology and contributing "Chinese wisdom" and "Chinese solutions" to the global life sciences field.
Since its debut in 2012, CRISPR/Cas9 technology has become one of the most revolutionary tools in life science research and disease treatment. This collaboration between YanYin Technology and ZhuanMa Bio not only overcomes technical barriers but also brings unprecedented innovation opportunities across industries through independent R&D.
01/ A Pioneering CRISPR Design Tool Empowering Precision Life Design
As a major upgrade to the molecular biology module of YanYin Technology's YanYin Research Cloud Platform, the new "CRISPR Tool" integrates ZhuanMa Bio's deep expertise in gene editing enzymes with YanYin Technology's powerful cloud-based scientific collaboration capabilities, providing researchers with a one-stop solution for gRNA (guide RNA) design and analysis in CRISPR-Cas9 systems, significantly improving the success rate and efficiency of gene editing experiments.
Key features include:
- Genome sequence import: Supports rapid import of target sequences by gene ID/name or chromosomal location.
- gRNA design: Automatically designs efficient guide RNA sequences.
- Off-target analysis: Predicts potential off-target sites and mismatch information.
- Primer design: Automatically generates PCR validation primers.
- Result saving: Conveniently saves design and analysis results to sequence files for easy management and sharing.
02/ Empowering Multi-Sector Applications, Reshaping the Future Landscape
With its superior intelligent algorithms, this CRISPR tool enables automatic design of efficient guide RNA sequences and prediction of potential off-target sites and mismatch information, profoundly impacting multiple key sectors.
In medical health, the CRISPR tool will power the development of new therapies to tackle genetic diseases and cancer; in agriculture and animal husbandry, it can accelerate crop and livestock improvement, significantly boosting yield and quality while shortening breeding cycles; in biotechnology and research institutions, it will serve as a powerful engine driving fundamental research and novel gene editing tool design; in environmental protection, it will provide unprecedented technical support for maintaining ecological balance and biodiversity.
03/ Deep Integration Forging an Innovation Engine
This collaboration exemplifies the complementary strengths and powerful partnership between YanYin Technology and ZhuanMa Bio. YanYin Technology, through its independently developed YanYin Research Cloud Platform and its robust molecular biology module, has accumulated a massive base of scientific and enterprise users, offering comprehensive basic research tools ranging from gene sequence editing and automatic primer design to molecular cloning.
ZhuanMa Bio possesses the globally leading ultra-compact, high-efficiency gene editor alphaCas®, and has built an AI-driven gene editor discovery platform integrating end-to-end CRISPR enzyme functional validation, gene editing efficiency assessment, and off-target analysis capabilities, enabling efficient and rapid target screening and pipeline development.
Through joint R&D of a next-generation CRISPR design application platform, the two companies have deeply integrated ZhuanMa Bio's cutting-edge gene editing technology with the YanYin Research Cloud Platform, delivering unprecedented convenience, precision, and efficiency to CRISPR gene editing users worldwide and greatly simplifying the design and analysis workflow of gene editing experiments.
"We are incredibly proud to partner with ZhuanMa Bio to launch this milestone CRISPR editor," said Zeping Chen, CEO of YanYin Technology. "This represents not only a major breakthrough for China's biotech sector but also our firm commitment to making cutting-edge technology accessible to all. We believe this tool will greatly accelerate the pace of life science research and have far-reaching impact on scientific and technological progress."
Looking ahead, YanYin Technology and ZhuanMa Bio will continue to deepen their collaboration, driving continuous innovation in technology R&D while strengthening joint market promotion efforts to bring the product to international markets. Together, they will empower researchers and enterprise users globally to write a new chapter in life sciences.
Past Highlights
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, the firm has focused on investing in outstanding early- and growth-stage companies in the Technology and Consumer (T&C) and Healthcare sectors.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have gone public on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many Qiming Venture Partners portfolio companies have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), UBTECH (09880.HK), WeRide (NASDAQ:WRD), Insta360 (688775.SH), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Berry Genomics (000710.SZ), SinoCellTech (688520.SH), Yuanxin Technology, Insilico Medicine, MediLink Therapeutics, LaNova Medicines, Zhipu AI, StepFun, Biren Technology, and others.